Trial reportRespiratory medicine2011
LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects.
Trial report in Respiratory medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Leukotriene inhibitors for bronchiolitis in infants and young children.The Cochrane database of systematic reviews · 2015Pooled it
- Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Tick-borne encephalitis virus transmitted singly and in duo with Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum bacteria by ticks as pathogens modifying lipid metabolism in human blood.Journal of biomedical science · 2024Article
- Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation.International journal of molecular sciences · 2022Article
- Salivary markers and coronavirus disease 2019: insights from cross-talk between the oral microbiome and pulmonary and systemic low-grade inflammation and implications for vascular complications.Cardiovascular endocrinology & metabolism · 2021Review
- Lipid droplets and lipid mediators in viral infection and immunity.FEMS microbiology reviews · 2021Review
- Role of arachidonic cascade in COVID-19 infection: A review.Prostaglandins & other lipid mediators · 2021Review
- The impact of coronavirus infectious disease 19 (COVID-19) on oral health.Oral diseases · 2021Article
- The roles of lipids in SARS-CoV-2 viral replication and the host immune response.Journal of lipid research · 2021Review
- What about COVID-19 and arachidonic acid pathway?European journal of clinical pharmacology · 2020Review
- Review
- Leukotriene BScientific reports · 2017Article
- Too much of a good thing: How modulating LTBSeminars in immunology · 2017Review
- The inflammatory response triggered by Influenza virus: a two edged sword.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- Leukotriene B4 Enhances NOD2-Dependent Innate Response against Influenza Virus Infection.PloS one · 2015Article
- Lack of group X secreted phospholipase A₂ increases survival following pandemic H1N1 influenza infection.Virology · 2014Article
- Neutrophils are needed for an effective immune response against pulmonary rat coronavirus infection, but also contribute to pathology.The Journal of general virology · 2014Article
- Leukotriene B4, an endogenous stimulator of the innate immune response against pathogens.Journal of innate immunity · 2014Review
- Antiviral mechanisms of human defensins.Journal of molecular biology · 2013Review
- Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection.Virology journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeukotriene B4 (LTB4) recruits and activates neutrophils. Accordingly, this leukotriene is involved in innate defense actions.
objectiveTo examine if nasal LTB4 can produce neutrophil activity and to explore whether or not LTB4 can condition neutrophils to exert virucidal effects in vitro and in vivo.
methods1. Twenty-three healthy subjects received nasal LTB4 in a randomized and sham-controlled design. Symptoms were scored and nasal lavages carried out. Myeloperoxidase (MPO) and α-defensins were monitored as indices of neutrophil activity. IL-8, eosinophil cationic protein (ECP) and α(2)-macroglobulin were measured as indices of pro-inflammatory cytokine production, eosinophil activity, and plasma exudation. 2. Supernatants from neutrophils activated by LTB4 in vitro were assayed for virucidal activity against respiratory viruses. 3. In 38 healthy individuals, nasal inoculation with human rhinovirus-16 (HRV-16) was performed. In a preliminary study, intervention with LTB4 was given in a randomized and controlled design. Symptoms, virus replication, and antibody-titres were monitored.
results1. LTB4 produced statistically significant increases in MPO and α-defensins, whereas IL-8, ECP, and α(2)-macroglobulin were unaffected. 2. The supernatants efficiently killed human coronavirus, respiratory syncytial virus, and influenza B virus. 3. HRV-16 replication was lower in subjects receiving LTB4, but this difference failed to reach statistical significance. Common cold symptoms and incidence of seroconversion were unaffected.
conclusionNasal LTB4 induces a selective recruitment/activation of neutrophils. LTB4 can condition neutrophils to exert virucidal effects in vitro and may reduce virus replication in vivo. We suggest that the condition induced by LTB4 reflects an enhanced state of innate defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.